Skip to main content
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1997 Jan;107(1):103–111. doi: 10.1046/j.1365-2249.1997.d01-885.x

The in vivo induction of lymphocyte apoptosis in MRL-lpr/lpr mice treated with FTY720

S SUZUKI *, X -K LI *, T SHINOMIYA *, S ENOSAWA *, H AMEMIYA *, M AMARI *, S NAOE *
PMCID: PMC1904563  PMID: 9010264

Abstract

The in vitro treatment of lpr thymocytes with FTY720 resulted in a dose-dependent reduction in cell viability due to apoptosis. In order to study the effect of FTY720 in vivo, lpr mice received an oral daily dose of 1 mg/kg FTY720 for 14 days, beginning at 16 weeks of age which was when the animals were developing massive lymphoadenopathy. Compared with untreated lpr mice, FTY720-treated lpr mice had significantly prolonged lives. At 24 weeks of age, treated mice demonstrated markedly reduced weights of the spleen and lymph nodes, and the proportion of CD3+B220+ and CD4CD8 cells in the thymus, spleen and lymph nodes decreased markedly. In addition, in these mice the percentage of CD4+CD8+ and CD3B220 cells in the thymus and the percentage of CD4+CD8, CD4CD8+, CD3+B220 and CD3B220+ cells in the spleen returned to almost the normal values observed in wild-type mice. Histological observation 1 day after the final administration of FTY720 revealed a remarkable infiltration of neutrophils in the lymphoid organs. Apoptotic cells were detected in all the lymphoid organs using in situDNA nick-end labelling. Electron microscopy showed that the apoptotic cells were ingested by phagocytes. FTY720 therapy is thus highly effective in Fas-mutant animals with abnormally expanding lymphocytes.

Keywords: FTY720, apoptosis, Isaria sinclairii, immunosuppressant, MRL-lpr/lpr mice

Full Text

The Full Text of this article is available as a PDF (3.5 MB).


Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES